MGC Pharmaceuticals has received permission to import psilocybin into Slovenia.
Europe-based MGC Pharmaceuticals has been granted its first import permit for 200g of Psilocybin Raw Mushroom material to its Slovenian research facility from Psyence Group.
The psilocybin will be shipped from Psyence’s production site in South Africa, and MGC Pharma will perform an analysis on the materials with a view to assisting Psyence in the development of new psilocybin products to take to market.
This will be done through MGC Pharma’s GMP-certified research facility in Slovenia that was recently approved for psilocybin compounding.
Roby Zomer, CEO and Managing Director of MGC Pharmaceuticals, stated: “We are delighted to receive the first import approval of psilocybin under our collaboration with Psyence, which constitutes our first entry into the psilocybin market.
“This partnership marks a significant milestone for MGC Pharma following our recent approval for psilocybin research in our Slovenian facility and reinforces our commitment to growth and innovation.
“By joining forces with Psyence, we are combining our respective strengths and expertise to unlock new opportunities and deliver exceptional value to our customers. This collaboration enhances our ambitions to be one of the first companies to provide Psilocybin treatments alongside our plant-based treatments.”
Director of Strategy and Head of Production at Psyence, Tony Budden, added: “Psyence Production is pleased to collaborate with MGC Pharma in the research and development of standardized psilocybin-containing products from our mushrooms.
“Having access to MGC’s EU-GMP R&D lab, expert team and resources will help accelerate this process and we look forward to working together.”
Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences, operating out of one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities in Southern Africa.
The company focuses on developing propriety natural psilocybin drug development and treatment protocols with a focus on palliative care, cultivating natural psilocybin mushrooms at its facility.
